ArticleInternational journal of clinical and experimental pathology2026
A five-gene mitochondria-associated prognostic signature for bladder cancer.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BLCA) is a common malignant tumor of the urinary system with a poor prognosis, especially in cases of invasive or advanced patients. Although mitochondrial dysfunction is associated with tumor progression, there are relatively few mitochondrial-related prognostic models for bladder cancer. The intention of study was to construct a five-gene mitochondrial-related prognostic marker for bladder cancer, and perform external validation, and then explore its association with the tumor immune microenvironment and potential immune treatment response.
methodsTranscriptome and clinical data were obtained from TCGA and GEO databases - intersecting bladder cancer-related differentially expressed genes (BLCA-related DEGs) with the mitochondrial-related gene database (MitoCarta 3.0 genes) to find the mitochondria-related differentially expressed genes (Mitochondria-related DEGs). Construction of a prognosis model using univariate (uni), lasso, and multivariate Cox regression analyses, was used for verificaiotn in 2 gene expression profile public databases (GEO cohorts). Functional enrichment (func enrich), tumor microenvironment (tumor microenv), immune infiltration (immune infil), mutation (mut), and single-cell transcriptomic analyses were carried out.
resultsA prognosis model was created containing five genes: COX7A1, MTHFD1L, MTG1, SCO2, and ACP6. The survival rate of high-risk patients was found to be poorer compared with that of low-risk patients. The high-risk tumor stromal score was higher, the fibroblast-related characteristics were enriched, with differences in the immune pattern. Single-cell analysis found COX7A1 in endothelial cells and mast cells, MTHFD1L in T cells, and SCO2 in endothelial cells. Functional analysis associated the high-risk group with extracellular matrix remodeling, stromal activation, and changes in immune pathways. This model also has potential value in estimating the response to immunotherapy.
conclusionsA five-gene prognosis marker related to mitochondria for bladder cancer was developed and verified. This model may become a useful tool for survival stratification of bladder cancer patients and characterization of tumor microenvironment heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.